累积临床危险因素负担分层预测视网膜裂孔激光 retinopexy 后需额外视网膜干预
本研究回顾性分析 285 眼因视网膜裂孔行首次激光 retinopexy 的患者,将玻璃体出血、多发性视网膜裂孔和裂孔旁视网膜下液定义为核心危险因素(各 1 分,共 0–3 分)。结果显示,随核心危险因素数量增加,需额外视网膜干预的比例从 0 个因素的 0.6% 逐步升至 1 个因素 22.9%、2 个因素 76.9%、3 个因素 100%(趋势 P < .001)。该简单计数框架可能有助于指导早期监测、患者咨询和随访计划。
要点
- 玻璃体出血、多发性裂孔、裂孔旁视网膜下液各自独立与额外干预相关(校正 OR 分别 22.0、18.4、17.3)。
- 核心危险因素数量与额外干预率呈分级增加:0 个 0.6%、1 个 22.9%、2 个 76.9%、3 个 100%。
- 额外干预中位时间 3.0 周(IQR 2.0–9.5 周),提示早期随访重要性。
核心结论
- 玻璃体出血、多发性视网膜裂孔和视网膜下液的累积数量与激光 retinopexy 后额外视网膜干预的分级增加相关。
- 该基于计数的简单框架可能有助于指导早期监测、患者咨询和随访规划。
研究设计与样本
- 核心危险因素为玻璃体出血、多发性视网膜裂孔和裂孔旁视网膜下液,各计 1 分,总分 0–3 分。
- 额外视网膜干预定义为补充激光、新裂孔激光、进展为孔源性视网膜脱离的手术或非清除性玻璃体出血的玻璃体切除术。
主要发现
- 随访期间 43 眼(15.1%)需额外视网膜干预,其中 32 眼行额外激光,11 眼行手术。
- 首次额外干预的中位时间为 3.0 周(四分位距 2.0–9.5 周)。
- 多变量 logistic 回归(校正其他两个核心因素)显示,玻璃体出血校正 OR 22.0(95%CI 6.09–79.6,P < .001)、多发性视网膜裂孔校正 OR 18.4(95%CI 5.81–58.0,P < .001)、视网膜下液校正 OR 17.3(95%CI 5.84–51.0,P < .001)均独立相关。
- 额外干预率随核心危险因素数量增加而升高:0 个 0.6%、1 个 22.9%、2 个 76.9%、3 个 100%(Cochran-Armitage 趋势检验 P < .001)。
- 三个因素均具备的组仅包含 3 眼。
关键数值与推荐
- 核心危险因素计数:玻璃体出血、多发性视网膜裂孔、裂孔旁视网膜下液各 1 分,总分 0–3 分。
- 额外干预率按 0、1、2、3 个因素分别为 0.6%、22.9%、76.9%、100%,趋势检验 P < .001。
- 多变量分析中三个核心因素的校正 OR 分别为 22.0、18.4、17.3,P 均 < .001。
临床怎么用
- 对于视网膜裂孔行激光 retinopexy 的患者,可计数玻璃体出血、多发性裂孔和视网膜下液三个核心因素以分层额外干预风险。
- 核心因素数量较多的患者额外干预率较高且中位时间约 3 周,应考虑早期加强监测和随访。
- 该计数框架可用于患者咨询,解释不同危险因素数量对应的额外干预风险分级。
局限性
- 回顾性单中心研究设计。
- 三个核心因素均具备的组仅 3 眼,该组结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to determine whether the cumulative burden of clinical risk factors at initial presentation stratifies the need for additional retinal intervention after laser retinopexy for retinal tears. DESIGN: Retrospective clinical cohort study. SUBJECTS: A total of 285 eyes of 285 patients who underwent initial laser retinopexy for retinal tears at a single tertiary referral center between April 2010 and December 2025. METHODS: The medical records were retrospectively reviewed. Vitreous hemorrhage, multiple retinal tears, and subretinal fluid adjacent to the retinal tear at initial presentation were designated as the core risk factors. Each factor was assigned 1 point, yielding a core risk factor count ranging from 0 to 3. Additional retinal intervention was defined as supplemental laser treatment to the initial tear, laser treatment for new retinal tears, surgery for progression to rhegmatogenous retinal detachment, or vitrectomy for nonclearing vitreous hemorrhage. MAIN OUTCOME MEASURES: Occurrence of any additional retinal intervention after initial laser retinopexy. RESULTS: During follow-up, 43 eyes (15.1%) required additional retinal intervention. Additional laser treatment was performed in 32 eyes, while surgical intervention was performed in 11 eyes. The median time to the first additional intervention was 3.0 weeks (interquartile range, 2.0-9.5 weeks). In the multivariable logistic regression analysis adjusted for the other two core factors, vitreous hemorrhage (adjusted odds ratio [OR], 22.0; 95% confidence interval [CI], 6.09-79.6; P < .001), multiple retinal tears (adjusted OR, 18.4; 95% CI, 5.81-58.0; P < .001), and subretinal fluid (adjusted OR, 17.3; 95% CI, 5.84-51.0; P < .001) were independently associated with additional retinal intervention. The rate of additional intervention progressively increased with the number of core risk factors: 0.6% with no factors, 22.9% with one factor, 76.9% with two factors, and 100% with three factors (Cochran-Armitage test for trend, P < .001). The group with all three factors included only three eyes. CONCLUSIONS: The cumulative number of vitreous hemorrhage, multiple retinal tears, and subretinal fluid was associated with a graded increase in additional retinal intervention after laser retinopexy. This simple count-based framework may help guide early surveillance, patient counseling, and follow-up planning.
引用
- Sano H, Yanai R, Hayahara Y, et al. Cumulative Clinical Risk Factor Burden Stratifies the Need for Additional Retinal Intervention After Laser Retinopexy for Retinal Tears. Am J Ophthalmol. 2026. PMID: 42731772. doi:10.1016/j.ajo.2026.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。